Accéder au contenu
Merck

Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation.

Circulation research (2014-05-03)
Johannes Weirather, Ulrich D W Hofmann, Niklas Beyersdorf, Gustavo C Ramos, Benjamin Vogel, Anna Frey, Georg Ertl, Thomas Kerkau, Stefan Frantz
RÉSUMÉ

An exaggerated or persistent inflammatory activation after myocardial infarction (MI) leads to maladaptive healing and subsequent remodeling of the left ventricle. Foxp3(+) CD4(+) regulatory T cells (Treg cells) contribute to inflammation resolution. Therefore, Treg cells might influence cardiac healing post-MI. Our aim was to study the functional role of Treg cells in wound healing post-MI in a mouse model of permanent left coronary artery ligation. Using a model of genetic Treg-cell ablation (Foxp3(DTR) mice), we depleted the Treg-cell compartment before MI induction, resulting in aggravated cardiac inflammation and deteriorated clinical outcome. Mechanistically, Treg-cell depletion was associated with M1-like macrophage polarization, characterized by decreased expression of inflammation-resolving and healing-promoting factors. The phenotype of exacerbated cardiac inflammation and outcome in Treg-cell-ablated mice could be confirmed in a mouse model of anti-CD25 monoclonal antibody-mediated depletion. In contrast, therapeutic Treg-cell activation by superagonistic anti-CD28 monoclonal antibody administration 2 days after MI led to improved healing and survival. Compared with control animals, CD28-SA-treated mice showed increased collagen de novo expression within the scar, correlating with decreased rates of left ventricular ruptures. Therapeutic Treg-cell activation induced an M2-like macrophage differentiation within the healing myocardium, associated with myofibroblast activation and increased expression of monocyte/macrophage-derived proteins fostering wound healing. Our data indicate that Treg cells beneficially influence wound healing after MI by modulating monocyte/macrophage differentiation. Moreover, therapeutic activation of Treg cells constitutes a novel approach to improve healing post-MI.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Formaldéhyde solution, for molecular biology, 36.5-38% in H2O
SAFC
Formaldéhyde solution, contains 10-15% methanol as stabilizer, 37 wt. % in H2O
Sigma-Aldrich
Formaldéhyde solution, for molecular biology, BioReagent, ≥36.0% in H2O (T)
Sigma-Aldrich
Formaldéhyde solution, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Supelco
Formaldéhyde solution, stabilized with methanol, ~37 wt. % in H2O, certified reference material
Sigma-Aldrich
Chlorure de dodécyltriméthylammonium, ≥99.0% (AT)
Sigma-Aldrich
Formaldéhyde solution, meets analytical specification of USP, ≥34.5 wt. %
Sigma-Aldrich
Formaldéhyde solution, tested according to Ph. Eur.
Sigma-Aldrich
Human Osteopontin ELISA Kit, for serum, plasma, cell culture supernatant and urine
Sigma-Aldrich
Formaldehyde-12C solution, 20% in H2O, 99.9 atom % 12C
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Sigma-Aldrich
Chlorure de dodécyltriméthylammonium, purum, ≥98.0% anhydrous basis (AT)
Sigma-Aldrich
Mouse Osteopontin ELISA Kit, for serum, plasma and cell culture supernatant